Scalper1 News
Pfizer (PFE) ended weeks of speculation on Wall Street by announcing Friday that it will file for U.S. approval of its breast-cancer drug palbociclib before it finishes clinical trials. The palbociclib FDA filing will be based on the mid-stage PALOMA-1 trial, according to Pfizer’s press release. Pfizer presented the final results of that trial last month, showing a strong progression-free survival benefit, but analysts debated whether it was Scalper1 News
Scalper1 News